Cargando…
Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression
SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) have dramatically changed the landscape of metastatic urothelial carcinoma (UC). However, optimal duration of treatment with ICI in the metastatic setting remains unclear. On the basis of real-world data from the Netherlands of patients treated with...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378071/ https://www.ncbi.nlm.nih.gov/pubmed/37509315 http://dx.doi.org/10.3390/cancers15143654 |